&w=3840&q=100)
Hindalco Industries to acquire US-based AluChem for $125 million
According to an exchange filing, the deal will be executed through Aditya Holdings LLC, a step-down wholly owned subsidiary of Hindalco. The acquisition is expected to close in the next quarter, subject to regulatory approvals in the United States.
AluChem produces high-grade specialty alumina
AluChem manufactures specialty alumina—including calcined, reactive, and tabular grades—used in sectors such as refractories, ceramics, and electronics. It operates three production facilities in Ohio and Arkansas, with a combined annual capacity of 60,000 tonnes.
In calendar year (CY) 2024, AluChem posted a turnover of $66.38 million, up 5.75 per cent from $62.76 million in CY2023. In CY2023, the company had seen an 8.26 per cent year-on-year decline from $68.42 million in CY2022. ALSO READ:
Specialty alumina is a high-purity aluminium oxide used in advanced technical applications across semiconductors, lithium-ion batteries, electronics, and aerospace, due to its exceptional thermal, mechanical, and electrical properties.
Hindalco aims to double specialty alumina capacity by FY30
Hindalco currently operates 500,000 tonnes of specialty alumina capacity and has set a target to scale up to 1 million tonnes by FY30. The business segment has shown consistent double-digit growth and contributes significantly to the company's high-margin revenue streams.
Strategic rationale and leadership commentary
'As alumina gains increasing relevance in critical and clean-tech sectors, AluChem's advanced chemistry capabilities will significantly enhance our ability to serve these fast-evolving markets,' said Satish Pai, Managing Director of Hindalco Industries.
Ronald Zapletal, Founder of AluChem, welcomed the deal, stating: 'This partnership with Hindalco brings AluChem the ability and capital to scale up faster and build scale in North America. Their ability to leverage R&D capabilities and a talented workforce adds tremendous value to our innovation pipeline, helping drive market expansion beyond North America.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
43 minutes ago
- India.com
Mukesh Ambani, Isha Ambani make big move, Reliance Retail acquires stake in this foreign company, it is of…, name of…
Home Business Mukesh Ambani, Isha Ambani make big move, Reliance Retail acquires stake in this foreign company, it is of…, name of… Mukesh Ambani, Isha Ambani make big move, Reliance Retail acquires stake in this foreign company, it is of…, name of… RRVL had reported a consolidated turnover of Rs 3.30 lakh crore for the year ended March 31, 2025. Reliance Retail Ventures Ltd (RRVL) has acquired a minority stake in UK-based FACEGYM for an undisclosed amount and plans to introduce the facial fitness and skincare brand in India, the company announced on Thursday. The investment is part of RRVL's broader strategy to expand its presence in the rapidly growing beauty and wellness segment. 'Through this partnership, Reliance Retail's Tira will spearhead FACEGYM's India foray – leading its local operations and market development, bringing the brand's innovative concept to the Indian consumer,' a joint statement said. Reliance To Establish FACEGYM In India Reliance will establish and scale FACEGYM's presence in India over the next five years, through a mix of standalone studios and curated spaces within select Tira stores across key cities, it said. Tira is an omnichannel beauty retail platform owned by Reliance Retail. 'This expansion will leverage Reliance's robust retail ecosystem, market expertise, and deep consumer insights to introduce and scale FACEGYM's unique offering in a rapidly growing beauty space,' it said. Founded by beauty and wellness entrepreneur Inge Theron, FACEGYM has pioneered a transformative approach to skincare by combining non-invasive facial workouts with advanced skincare formulations. 'The partnership reinforces Reliance Retail's broader strategy to scale its presence in the beauty and personal care vertical, anchored by Tira,' it said. Bhakti Modi On FACEGYM Bhakti Modi, Co-founder & CEO of Tira, said: 'FACEGYM sits at the unique intersection of beauty, wellness, and fitness – creating a category of its own. This aligns perfectly with the discerning beauty consumer in India who is experience-oriented, and increasingly drawn to science-backed, innovative concepts.' Angelo Castello, CEO of FACEGYM, said, 'With our current strategic partnerships, we are in a powerful position to turn FACEGYM into one of the only beauty services. This partnership with a leading conglomerate like Reliance will serve as a catalyst for our global expansion by establishing our presence in the dynamic Indian market.' RRVL, through its subsidiaries and affiliates, operates an integrated omni-channel network of 19,340 stores and digital commerce platforms across grocery, consumer electronics, fashion & lifestyle and pharma consumption baskets. (With Inputs From PTI) For breaking news and live news updates, like us on Facebook or follow us on Twitter and Instagram. Read more on Latest Business News on
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Carlyle Group may sell 10% stake in Piramal Pharma via block deals: Report
United States-based private equity firm Carlyle Group is planning to divest up to 10 per cent stake in Piramal Pharma through block deals, Moneycontrol reported on Thursday, citing sources. The sale could amount to ₹2,600-2,700 crore, the report added. Piramal Pharma sold 20 per cent of its stake to Carlyle Group in June 2020, in a deal worth ₹3,523 crore. According to stock exchange data, it held 18 per cent stake in the pharma firm as of March 31, 2025. Financial services firm Motilal Oswal has been roped in to facilitate the block deals, the report added. Piramal Pharma operates a diverse and global pharmaceutical business, providing a broad range of products and services. It includes Piramal Pharma Solutions (PPS), a fully integrated contract development and manufacturing organisation (CDMO); Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. Piramal Pharma Q4 result In the fourth quarter of FY25, Piramal Pharma posted a consolidated revenue from operations of ₹2,754 crore, marking an 8 per cent increase over the ₹2,552 crore recorded in the same quarter last year. The company's EBITDA (earnings before interest, tax, depreciation, and amortisation) also increased by 8 per cent year-on-year to ₹603 crore, up from ₹556 crore. Profit after tax (before exceptional items) came in at ₹154 crore, reflecting a 16 per cent rise compared to ₹132 crore in the corresponding period of the previous financial year. Shares of Piramal Pharma last traded at ₹202.4 apiece on the BSE at the close of the markets on Thursday.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Matter Motor has magnet stock for 3-4 months, exploring alternatives: COO
Matter Motor's COO, Arun Pratap Singh, discusses the company's approach to tackling supply disruptions caused by rare earth magnet shortages and its plans to explore alternative technologies Deepak Patel New Delhi Listen to This Article Electric motorcycle startup Matter Motor has sufficient rare earth magnets to sustain production for three to four months but is actively exploring alternatives, said its Founder Arun Pratap Singh in an interview with Business Standard on Thursday. The Ahmedabad-based firm, which has raised $75-80 million since 2019, is working to avoid supply disruptions following China's curbs on rare earth exports. 'Not today. We have got stock for three to four months. But it will become a problem,' Singh said when asked about the impact of the shortage. 'I was in China sometime back. We had a meeting (with our supplier).
